ArticleACS applied materials & interfaces2025
Oleic Acid Integrated Acetalated Dextran Nanoparticles for Enhanced Chemotherapeutic Delivery to the Bone Marrow.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bone marrow targeted delivery of chemotherapeutics remains critical in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL). Current drug delivery platforms to treat ALL do not specialize in enhancing drug accumulation in the bone marrow, often leading to suboptimal therapeutic responses and off-target side effects. Here, we developed a polymeric lipid hybrid nanoparticle (PLHP) platform through integration of a pH-responsive acetalated dextran (Ac-Dex) polymer and oleic acid (OA), an endogenous bone marrow-rich fatty acid, for enhanced accumulation of therapeutic payloads to bone marrow. PLHPs formulated using the flash nanoprecipitation were monodisperse with sizes below 200 nm and allowed encapsulation of diverse payloads. Of note, lyophilized PHLPs retained greater than 80% of encapsulated payloads following rehydration. Confocal imaging confirmed precise intracellular release of hydrophilic and hydrophobic payloads in B-cell ALL cell lines. In healthy BALB/c mice and B-cell ALL bearing NSG mice, we demonstrate that incorporation of OA into the Ac-Dex nanoparticles enhances payload accumulation in the femur and tibia compared to non-OA containing nanoparticles. In the B-cell ALL disease model, vincristine encapsulated into Ac-Dex OA nanoparticles significantly improved the survival of mice while preserving locomotor function, and mitigated terminal weight loss as compared to the systemically administered free drug and blank nanoparticles. Together, these findings show the promising translational potential of oleic acid integrated Ac-Dex nanoparticles for clinical use in bone marrow-derived diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.